PTC Therapeutics (PTCT) Beats Q1, Raises 2026 Revenue Guidance

PTC Therapeutics (NASDAQ: PTCT) Beats Q1 Expectations, Raises 2026 Revenue Guidance

• PTC Therapeutics significantly surpassed first-quarter loss-per-share expectations, reporting a GAAP loss of $0.03 per share versus analyst expectations for a much larger loss.
• The biopharmaceutical company reported Q1 2026 total revenue of $272.6 million, exceeding estimates and supported by strong Sephience revenue of $124.6 million.
  PTC Therapeutics raised its full-year 2026 product revenue guidance to $750 million to $850 million, reflecting confidence in the Sephience launch and broader commercial portfolio.

PTC Therapeutics (NASDAQ: PTCT) is a biopharmaceutical company focused on discovering, developing, and commercializing medicines for rare disorders. The company develops treatments for patients with serious diseases that often have limited therapeutic options.

On May 7, 2026, PTC Therapeutics reported a first-quarter GAAP net loss of $2.8 million, or $0.03 per share. This was substantially better than analyst expectations for a larger loss. Quiver Quantitative listed the estimate at a loss of $0.48 per share.

PTC Therapeutics also reported Q1 2026 total revenue of $272.6 million, versus an estimate of about $223.18 million. A key driver of the quarter was Sephience, which generated $124.6 million in first-quarter net product revenue. The company said Sephience revenue grew 36% from the fourth quarter of 2025, supported by continued U.S. momentum and expanding international contributions.

Following the strong quarter, PTC raised its full-year 2026 product revenue guidance to a range of $750 million to $850 million and projected total revenue of $1.08 billion to $1.18 billion. PTC ended the quarter with $1.89 billion in cash, cash equivalents, and marketable securities.